



THOMSON MEDICAL GROUP LIMITED

(Incorporated in the Republic of Singapore)
(Company Registration No. 199908381D)

RESTORATION OF PUBLIC FLOAT

1. INTRODUCTION

The Board of Directors (the “**Board**”) of Thomson Medical Group Limited (the “**Company**”) refers to the following announcements:

- (a) the announcement dated 12 September 2023 in relation to the loss of public float of the Company;
- (b) the announcement dated 19 September 2023 in relation to the Singapore Exchange Securities Trading Limited’s (the “**SGX-ST**”) confirmation that it has no objection to granting the Company a period of 3 months until 10 December 2023 for the public float to be restored and to not suspend trading in the Company’s shares on the SGX-ST in the meantime;
- (c) the announcement dated 7 December 2023 in relation to the SGX-ST granting the Company a further 1-month period till 10 January 2024 to explore options to restore the public float and the continued trading of the Company’s shares during this period;
- (d) the announcement dated 10 January 2024 in relation to the SGX-ST’s letter received by the Company on the same date rejecting the Company’s application for a further extension of time to restore the public float; and
- (e) the announcements dated 17 January 2024 in relation to the SGX-ST granting the Company a further 3-month period till 10 April 2024 to explore options to restore its public float and the continued trading of the Company’s shares during this period, based on the further submissions the Company had made to the SGX-ST in its appeal on 12 January 2024.

2. RESTORATION OF PUBLIC FLOAT

The Company is pleased to announce that following the sale of an aggregate of 50,000,000 shares, representing 0.19% of the share capital of the Company, by the controlling shareholder of the Company via married deals on the SGX-ST and an internal verification by the Company, the public float has today been restored to 10.15% of the issued share capital of the Company (excluding treasury shares), representing 2,685,007,380 shares held by more than 8,000 public shareholders. Accordingly, the Company complies with the requirement under Rule 723 of the Listing Manual of the SGX-ST.

3. CAUTION IN TRADING

Shareholders and investors are advised to exercise caution when dealing in the securities of the Company. Shareholders and investors should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions they should take.

**By Order of the Board
THOMSON MEDICAL GROUP LIMITED**

Dr Heng Jun Li Melvin
Executive Director and Group CEO
4 April 2024